Summary
The biochemical background of the intestinal side effects of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) and cis-diisopropylammine-trans-dihydroxy-dichloro platinum (IV) (CHIP) was compared with those of cis-diamminedichloroplatinum (II) (CDDP). Biochemical investigations were carried out on mucosal cells isolated by a combined chemical-mechanical method from the total length of the small intestine. After treatment with single, equitoxic doses of Pt analogues, the activities of thymidine kinase (TK) EC 2.7.1.21, sucrase (SUC) EC 3.2.1.26, maltase (MAL) EC 3.2.1.20, and protein content showed dose-dependent decreases, whereas the activity of alkaline phosphatase (AP) EC 3.2.1.20 increased slightly. The nadir of enzyme activity changes occurred 24–48 h after treatment. For the regeneration of the mucosa more than 96 h was necessary. Of the platinum analogues studied, CHIP proved to be the most toxic to the small intestine. While the highest doses of CDDP and CBDCA (0.66xLD50) caused significant but less than 50% decreases in TK, SUC, MAL, and protein content (PROT), the CHIP doses needed for 50% reduction were between 0.44–0.66xLD50.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allan SG, Smyth JF (1986) Small intestinal mucosal toxicity of cis-platinum, comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer 53: 355
Bessey OA, Lowry OH, Brock MI (1965) Determination in serum with p-nitrophenylphosphate. In: Bergmeyer HU (ed) Methods of enzymatic analysis. Verlag Chemie, Weinheim/Academic Press, New York London, p 783
Bodenner DL, Dedon PC, Keng PC, Borch RF (1986a) Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum (II) induced cytotoxicity, DNA cross-linking and γ-glutamyl transpeptidase inhibition. Cancer Res 46: 2745
Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF (1986b) Selective protection against cis-diamminedichloroplatinum (II) induced toxicity in kidney, gut and bone marrow by diethyldithiocarbamate. Cancer Res 46: 2751
Borison HL, McCarthy LE (1983) Neuropharmacology of chemotherapy-induced emesis. Drugs 25 [Suppl 1]: 8
Burholt DL, Schenken LL, Kovács CJ, Hagemann RE (1979) Response of the murine gastrointestinal epithelium to cis-dichlorodiammineplatinum (II): readiation combinations. Int J Radiat Oncol Biol Phys 5: 1377
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker MJ, Peckham MJ, Harrap KR (1982) Early clinical trials with cis-diammine-1,1-cyclobutane dicarboxylate platinum (II). Cancer Chemother Pharmacol 9: 140
Creaven PJ, Madajewicz S, Pendyala L, Mittelman A, Pontes E, Spaulding M, Arbuck S, Solomon J (1983) Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylammine platinum (IV) CHIP. Cancer Treat Rep 67: 795
Dahlqvist A (1968) Assay of intestinal disaccharidases. Anal Biochem 22: 99
Elliot WC, Newcom SR, Houghton DC, Baines-Hunter J, Bennett WM (1983) cis-Diamminedichloroplatinum (II) nephrotoxicity: tubular function after rescue with sodium diethyldithiocarbamate in rats. Cancer Res 43: 3759
Hartree EF (1970) Determination of protein. A modification of the Lowry method which gives a linear photometric response. Anal Biochem 48: 422
Hayes PM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High-dose cis-platinum diammine dichloride, amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372
Howell SB, Pfeile CL, Wung WE, Olshen RA (1983) Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43: 1426
Iwamoto Y, Kawano T, Ishizawa M, Aoki K, Kuroiwa T, Baba T (1985) Inactivation of cis-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits. Cancer Chemother Pharmacol 15: 228
Klemperer C, Haynes J (1968) Thymidine kinase in rat liver during development. Biochem J 108: 541
Kralovánszky J, Prajda N, Kerpel-Fronius S, Szentirmay Z (1981) Biological model system for investigating gastrointestinal side effects caused by cytostatic agents. In: Mózsik G, Hänninen O, Jávor T (eds) Gastrointestinal defence mechanisms. Pergamon Press, London/Akadémiai Kiadó, Budapest, p 327
Kralovánszky J, Prajda N, Kerpel-Fronius S, Gál F, Szentirmay Z (1983) Effect of a single high dose and repeated small doses of dianhydrogalactitol (DAG NSC-132313) on rat small intestinal mucosa. Cancer Chemother Pharmacol 11: 167
Lelieveld P, Van Der Vijgh JF, Veldhuizen RW, Van Velzen D, Van Putten LM, Atassi G, Danguy A (1984) Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer Clin Oncol 20: 1087
Osman NM, Copley MP, Litterst CL (1984) Amelioration of cisplatin induced nephrotoxicity by the diuretic acetazolamide in F 344 rats. Cancer Treat Rep 68: 1269
Pera MF, Zook BC, Harder HC (1979) Effect of mannitol and furosemide diuresis on the nephrotoxicity and physiological disposition of cis-diamminedichloroplatinum (II) in rats. Cancer Res 39: 1269
Prajda N, Kralovánszky J, Kerpel-Fronius S, Gál F, Szentirmay Z (1985) Enzymological and morphological changes in rat intestinal mucosa following treatment with alkylating sugar alcohol derivatives. Anticancer Res 5: 451
Walker EM, Gale GR (1981) Methods of reduction of cisplatin nephrotoxicity. Ann Clin Lab Sci 11: 397
Weiser MM (1973) Intestinal epithelial cell surface membrane glycoprotein synthesis. J Biol Chem 248: 2536
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kralovánszky, J., Prajda, N., Kerpel-Fronius, S. et al. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP). Cancer Chemother. Pharmacol. 21, 40–44 (1988). https://doi.org/10.1007/BF00262736
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262736